1.Construction of a Disease-Syndrome Integrated Diagnosis and Treatment System for Gastric "Inflammation-Cancer" Transformation Based on Multi-Modal Phenotypic Modeling
Hao LI ; Huiyao ZHANG ; Wei BAI ; Tingting ZHOU ; Guodong HUANG ; Xianjun RAO ; Yang YANG ; Lijun BAI ; Wei WEI
Journal of Traditional Chinese Medicine 2025;66(5):458-463
By analyzing the current application of multi-modal data in the diagnosis of gastric "inflammation-cancer" transformation, this study explored the feasibility and strategies for constructing a disease-syndrome integrated diagnosis and treatment system. Based on traditional Chinese medicine (TCM) phenomics, we proposed utilizing multi-modal data from literature research, cross-sectional studies, and cohort follow-ups, combined with artificial intelligence technology, to establish a multi-dimensional diagnostic and treatment index system. This approach aims to uncover the complex pathogenesis and transformation patterns of gastric "inflammation-cancer" progression. Additionally, by dynamically collecting TCM four-diagnostic information and modern medical diagnostic information through a long-term follow-up system, we developed three major modules including information extraction, multi-modal phenotypic modeling, and information output, to make it enable real-world clinical data-driven long-term follow-up and treatment of chronic atrophic gastritis. This system can provide technical support for clinical diagnosis, treatment evaluation, and research, while also offering insights and methods for intelligent TCM diagnosis.
3.Expert consensus on the application of nasal cavity filling substances in nasal surgery patients(2025, Shanghai).
Keqing ZHAO ; Shaoqing YU ; Hongquan WEI ; Chenjie YU ; Guangke WANG ; Shijie QIU ; Yanjun WANG ; Hongtao ZHEN ; Yucheng YANG ; Yurong GU ; Tao GUO ; Feng LIU ; Meiping LU ; Bin SUN ; Yanli YANG ; Yuzhu WAN ; Cuida MENG ; Yanan SUN ; Yi ZHAO ; Qun LI ; An LI ; Luo BA ; Linli TIAN ; Guodong YU ; Xin FENG ; Wen LIU ; Yongtuan LI ; Jian WU ; De HUAI ; Dongsheng GU ; Hanqiang LU ; Xinyi SHI ; Huiping YE ; Yan JIANG ; Weitian ZHANG ; Yu XU ; Zhenxiao HUANG ; Huabin LI
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(4):285-291
This consensus will introduce the characteristics of fillers used in the surgical cavities of domestic nasal surgery patients based on relevant literature and expert opinions. It will also provide recommendations for the selection of cavity fillers for different nasal diseases, with chronic sinusitis as a representative example.
Humans
;
Nasal Cavity/surgery*
;
Nasal Surgical Procedures
;
China
;
Consensus
;
Sinusitis/surgery*
;
Dermal Fillers
4.Amyloid-like fibrils derived from β-sheets of gp120 contribute to the neuronal pathology of HIV-associated neurocognitive disorders.
Chan YANG ; Ruyu WANG ; Chen CHENG ; Jiaqi YU ; Kunyu LU ; Haobin LI ; Jinshen WANG ; Guodong HU ; Hao YANG ; Jianfu HE ; Hao SU ; Qingping ZHAN ; Suiyi TAN ; Tong ZHANG ; Shuwen LIU
Acta Pharmaceutica Sinica B 2025;15(4):2273-2277
5.Current status and progress of new technologies in the diagnosis of tuberculous meningitis
Yicheng LI ; Ting WANG ; Wenmian HUANG ; Guodong FENG
Chinese Journal of Neurology 2024;57(3):302-308
Tuberculous meningitis is a central nervous system infectious disease caused by Mycobacterium tuberculosis. Its clinical manifestations are nonspecific, and effective pathogenic diagnostic methods are lacking, which often lead to delayed diagnosis and treatment, impacting the prognosis of patients. Therefore, early and rapid etiological diagnosis is crucial for the diagnosis and treatment of tuberculous meningitis. This article provides a review of novel detection technologies developed in recent years that can be used for the diagnosis of tuberculous meningitis, covering nucleic acid detection methods, metabolomics, and proteomics, and offering prospects for future development.
6.Penile protection with a self-developed flexible sleeve penile protection device after circumcision: a prospective randomized controlled trial
Pengfei TUO ; Kewei CHEN ; Xinchen LIU ; Guodong ZHU ; Huixing HE ; Tao CAI ; Yuxuan LI ; Xun ZHAO ; Liyuan GE ; Shudong ZHANG ; Lulin MA ; Wei GUO ; Zhuo LIU
Journal of Modern Urology 2024;29(4):363-367
【Objective】 To investigate the protective effects of aflexible sleeve penile protection device on reducing postoperative pain and wound edema in patients after circumcision. 【Methods】 A total of 54 patients who underwent circumcision at Yan’an Branch of Peking University Third Hospital during Feb.1 and May 31, 2023 were enrolled.The patients were randomly divided into the experimental group and control group, with 27 patients in either groups.Patients in the experimental group were treated with a flexible sleeve penis protection device after surgery, and patients in the control group were treated with traditional gauze bandage after surgery.Postoperative pain, wound edema and complications were compared between the two groups. 【Results】 In terms of pain, the visual analogue scale of the experimental group was significantly lower at 6 hours [(1.7±0.9) vs.(3.3±1.9), P<0.001] and 2 days [(2.0±1.3) vs.(3.3±1.3), P<0.001] after surgery than that of the control group, but there were no statistically significant differences between the two groups on the 4th and 7th postoperative days (P>0.05).In terms of edema, the edema score of the experimental group was significantly lower than that of the control group on the 2nd postoperative day [(2.0±1.0) vs.(4.0±0.8), P<0.001] , the 4th postoperative day [(1.5±1.2) vs.(2.6±0.9), P<0.001] , and the 7th postoperative day [(0.9±1.3) vs.(2.3±1.5), P<0.001] .There was no statistically significant difference in the incidence of complications between the two groups (P>0.05). 【Conclusion】 The flexible sleeve penile protection device has significant effects of reducing early postoperative pain and reducing edema in patients undergoing circumcision.
7.Research on the role of resveratrol against breast cancer
Qingdong GAO ; Xufang DUAN ; Yan LI ; Tao XU ; Yangyang YU ; Guodong BAI
China Pharmacy 2024;35(11):1408-1412
Breast cancer (BC) ranks first in the incidence rate of female malignant tumor, the notable features of which include high invasive behavior, high malignant degree and poor prognosis. Resveratrol, a plant antioxidant, has been identified as a potential therapeutic agent for the occurrence and progress of BC. This article explores the mechanism of resveratrol intervention in BC by evaluating several in vitro and in vivo studies. It was found that resveratrol can weaken the proliferation and survival ability of BC cells, suppress their growth, metastasis, and invasion, and reverse their resistance to adriamycin by promoting cell apoptosis, regulating autophagy, inhibiting glycolysis and regulating the tumor microenvironment, expressions of matrix metalloproteinases, epithelial-mesenchymal transition and drug-resistant proteins, etc. The limited number of clinical trial studies on resveratrol, mainly focusing on prevention effect of it on breast cancer, may be one of the reasons that affect the comprehensive evaluation of the anti-cancer efficacy of resveratrol.
8.Research on the role of resveratrol against breast cancer
Qingdong GAO ; Xufang DUAN ; Yan LI ; Tao XU ; Yangyang YU ; Guodong BAI
China Pharmacy 2024;35(11):1408-1412
Breast cancer (BC) ranks first in the incidence rate of female malignant tumor, the notable features of which include high invasive behavior, high malignant degree and poor prognosis. Resveratrol, a plant antioxidant, has been identified as a potential therapeutic agent for the occurrence and progress of BC. This article explores the mechanism of resveratrol intervention in BC by evaluating several in vitro and in vivo studies. It was found that resveratrol can weaken the proliferation and survival ability of BC cells, suppress their growth, metastasis, and invasion, and reverse their resistance to adriamycin by promoting cell apoptosis, regulating autophagy, inhibiting glycolysis and regulating the tumor microenvironment, expressions of matrix metalloproteinases, epithelial-mesenchymal transition and drug-resistant proteins, etc. The limited number of clinical trial studies on resveratrol, mainly focusing on prevention effect of it on breast cancer, may be one of the reasons that affect the comprehensive evaluation of the anti-cancer efficacy of resveratrol.
9.Application of Matching-adjusted Indirect Comparison Methods in Efficacy Evaluation of Traditional Chinese Medicine
Guodong LI ; Xinyu HU ; Huijuan CAO
Journal of Traditional Chinese Medicine 2024;65(23):2413-2418
Randomized controlled trials (RCTs) have been widely used in clinical efficacy evaluation of traditional Chinese medicine (TCM), but also having limitations such as high cost,time consuming, and difficulty in patient recruitment and enrollment. The introduction of matching adjusted indirect comparison (MAIC) can alleviate the problem caused by the limitation of traditional RCT methodology to some extent. This paper introduced the basic principles of MAIC, and analyzed the similarities and differences, advantages and disadvantages of the two design methods, that is the anchored and the non-anchored. By analyzing two case studies in the evaluation of TCM efficacy, which are acupuncture for paroxysmal migraine and moxibustion for diarrhea-type irritable bowel syndrome, respectively, this paper introduced the methodological characteristics of MAIC in the efficacy evaluation of TCM, explored the strengths and feasibility of MAIC in the evaluation of efficacy evidence in TCM, the evaluation of efficacy of non-pharmacological TCM therapy and the development of new Chinese medicine, and discussed the limitations of existing research, matching factors and sample size. Additionally, the paper offered prospects by combining the simulation treatment comparison method and emulated target trials, with the goal of providing recommendations and references for the clinical efficacy evaluation of TCM.
10.Single-arm, Multi-center, Prospective Clinical Study of Recombinant Human Endostatin Combined with Afatinib and Teggio in Second-line Treatment of Advanced Lung Squamous Cell Carcinoma
Yang CHEN ; Guodong FAN ; Annan JIAO ; Zegeng LI ; Jiabing TONG ; Biao FANG ; Suling YAO ; Mingqi WANG ; Mei ZHANG ; Ping LI
Chinese Journal of Modern Applied Pharmacy 2024;41(10):1388-1393
OBJECTIVE
To evaluate the effictiveness and safety of recombinant human endostatin combined with afatinib and teggio in the treatment of advanced lung squamous cell carcinoma.
METHODS
A total of 25 patients with driver-negative advanced lung squamous cell carcinoma were included in this single-arm prospective study, and the enrolled patients were treated with recombinant human endostatin combined with afatinib and teggio as scheduled. Progression-free survival(PFS), overall survival(OS), disease control rate(DCR), objective response rate(ORR), and adverse reactions(AR) were observed and analyzed.
RESULTS
The 25 enrolled patients received at least 2 cycles of second-line treatment, and were followed up as of March 31, 2023. Among them, 4 patients had partial remission, 17 patients had stable disease, and 4 patients experienced progressive disease. The ORR confirmed by the researchers was 16%(95%CI, 4.5%−36.1%), DCR was 84%(95%CI, 63.9%−95.5%), and median PFS was 5.3 months(95%CI, 3.5−6.9 months). The median OS had not yet been achieved. The entire group of patients had good treatment tolerance, and the most common level Ⅲ or Ⅳ adverse events related to treatment were leukopenia(20%) and rash(12%), with no reported treatment-related deaths.
CONCLUSION
Recombinant human endostatin combined with afatinib and teggio in the second line treatment of advanced lung squamous cell carcinoma can prolong the progression free survival period of patients and is relatively safe, which is worth further exploration and promotion.


Result Analysis
Print
Save
E-mail